Navigation Links
Study Details New Molecular Approach to Preventing Alzheimer's
Date:4/24/2008

The concept calls for targeting an enzyme within brain cells

THURSDAY, April 24 (HealthDay News) -- German researchers are reporting a new approach to the possible prevention of the molecular "debris" that's associated with the development of Alzheimer's disease.

The basic idea -- to block the activity of an enzyme called beta-secretase -- is not new, said study lead author Dr. Kai Simons, a professor of cell biology at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden.

A number of laboratories, both academic and commercial, are working on methods to prevent the enzyme from slicing a protein into beta amyloid fragments that form the brain plaques found in people with the disease. All work on the same principle. "If we decrease the amount of cleavage, we could in all likelihood reduce the likelihood of the disease," Simons said.

Most experts now agree that formation of the beta amyloid plaques is directly linked to the development of Alzheimer's. The problem with most proposed methods of blocking beta-secretase, Simons said, is that they are designed to work outside of the affected brain cells.

"This process of cleaving takes place inside cells," he said. "We have constructed an inhibitor which binds outside, on the cell membrane, and goes into the cell where the cleavage occurs."

Reporting in the April 25 issue of the journal Science, Simons and his colleagues described both test-tube experiments and animal studies in which the combination of an anchoring molecule and a beta-secretase inhibitor reduced the formation of beta amyloid plaque by more than 50 percent over four hours, while the inhibitor alone was ineffective.

The success is just one small step toward a medically useful preventive therapy for Alzheimer's disease, Simons acknowledged. For one thing, the treatment was given by injection into the brains of the experimental animals (fruit flies and mice), something not likely to be done with people.

"This is proof of principle," Simons said. "The idea would be to get it into the blood in humans and then over the blood-brain barrier into the brain. There are many ways for molecules to get into the brain."

The blood-brain barrier is a network of tightly packed cells that prevents most molecules from entering the brain.

William J. Netzer, an Alzheimer's researcher at the Fisher Center for Alzheimer's Disease Research Foundation at Rockefeller University in New York City, called the new study "a profoundly interesting line of research."

"It is not implausible that one might improve the effectiveness of a drug by coaxing it to go into a region where the enzymes it blocks exist," Netzer said.

But medical use of such a product can raise questions, he said. "When you put an inhibitor into a living being, the chemical you put in can be modified in the body. Where a compound goes into a cell is a complicated issue when you put it into a human being," he added.

Dr. James Galvin, associate professor of neurology and psychiatry at Washington University in St. Louis, called the German research "a novel idea."

If the concept works, it would solve a puzzle about how to best target the enzyme, Galvin said. And it is a concept with broader medical possibilities, he said.

"You can potentially inhibit other enzymes where cleavage occurs within membranes," he said.

More information

Learn more about Alzheimer's disease from the U.S. Library of Medicine.



SOURCES: Kai Simons, M.D., Ph.D., professor of cell biology, Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany; William J. Netzer, Ph.D., research associate, Fisher Center for Alzheimer's Disease Research Foundation, Rockefeller University, New York City; James Galvin, M.D., associate professor of neurology and psychiatry, Washington University, St. Louis; April 25, 2008, Science


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. NSF awards $1.5M for study of in-home health care via wireless networks
2. Study shows positive findings in treating patients with advanced hepatitis C
3. Study finds racial disparities in smoking cessation treatment
4. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
5. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
6. Study finds that competency in colonoscopy requires experience with 150 cases or more
7. Study finds cisplatin less effective than standard treatment for patients with anal cancer
8. Potential viral therapy weapon for difficult cancers is safe and effective in study
9. Study: Counseling trauma victims causes secondary trauma
10. Rat study suggests why teens get hooked on cocaine more easily than adults
11. Study Shows Increased Out-of-Pocket Expenses May Negatively Influence Initiation of TNF Blocker Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... and which He does not. Yisrayl says with so many titles and names for ... but he says with a little Scripture, backed with a lot of research, the truth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA is ... Côté has 20+ years of experience within the beauty industry, ranging from marketing, ... array of high-end cosmetic brands, retail brands and outlets in Canada and New ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... advanced nutraceutical supplements, through its Nova Skin Sciences division, recently announced the launch ... a moisturizer with the power of an anti-aging concentrate. , Anogeissus ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different movies ... as the host of the “Informed” series. The program focuses on many important issues ... focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, ...
(Date:4/28/2017)... ... ... Christie Medical Holdings, Inc. , with its market-leading vein finder ... a leader in infusion therapy and pain management. , Intravenous (IV) therapy plays ... patients receiving a peripheral IV catheter as part of their treatment plan. Many hospitals ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
Breaking Medicine Technology: